AI Terminal
Advicenne
Report Publication Announcement • Nov 28, 2024
1079_iss_2024-11-28_ce7c26de-584a-494d-9774-3e4172d5f563.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
Advicenne announces its 2025 financial calendar
Paris (France), November 28, 2024 – 6.00 pm CET – Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering from rare renal diseases, announces its 2025 financial communication calendar.
| Event | Date* |
|---|---|
| 2024 sales release | January 23, 2025 |
| 2024 annual financial statement | March 27, 2025 |
| AGM | May 15, 2025 |
| 2025 First Half financial statement | September 18, 2024 |
*: subject to change. End of trading
About Advicenne
Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal® (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU and GB. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information, see: https://advicenne.com/.
CONTACTS
Advicenne Didier Laurens, CEO +33 (0)1 87 44 40 17 Email: [email protected] Ulysse Communication Media relations Bruno Arabian +33 (0)6 87 88 47 26 Email: [email protected]
Disclaimer
This press release contains certain forward-looking statements concerning Advicenne group and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Advicenne considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2023 Universal Registration Document filed with the French financial market authority on April 5, 2024 (a copy of which is available on www.advicenne.com) and to the development of economic conditions, financial markets and the markets in which Advicenne operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Advicenne or not currently considered material by Advicenne. The occurrence of all or part of such risks could cause actual results, financial conditions, performance, or achievements of Advicenne to be materially different from such forward-looking statements. Advicenne expressly declines any obligation to update such forward-looking statements.